Key result
ApoC3 inhibitor volanesorsen cuts triglycerides ~75% and reduces pancreatitis in familial chylomicronemia syndrome.
Why the study?
Severe hypertriglyceridaemia causes pancreatitis, but familial chylomicronaemia syndrome has few long-term management options beyond dietary fat restriction, with variable responses to fibrates and statins.
Does volanesorsen reduce triglyceride levels and pancreatitis in patients with familial chylomicronaemia syndrome or familial partial lipodystrophy?
Does volanesorsen reduce triglyceride levels and pancreatitis in patients with familial chylomicronaemia syndrome or familial partial lipodystrophy?
Volanesorsen, an apoC3 inhibitor, offers a promising targeted therapy for reducing severe hypertriglyceridemia and associated pancreatitis in rare genetic lipid disorders like FCS and FPLD.
No takes yet. Share an insight, caveat, or question.
May support targeted therapy in refractory FCS; leaves open confirmation in FPLD pending higher-quality trials.
Esan et al. (2020) conducted a review in Familial Chylomicronemia Syndrome or Hypertriglyceridaemia. Volanesorsen was evaluated on Triglyceride levels. Volanesorsen, an antisense oligonucleotide inhibitor of apolipoprotein C3, reduces triglyceride levels by 70-80% and reduces rates of pancreatitis in familial chylomicronemia syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: